Eliem Therapeutics Inc (ELYM)
7.59
-0.07
(-0.91%)
USD |
NASDAQ |
May 31, 16:00
7.68
+0.09
(+1.19%)
After-Hours: 20:00
Eliem Therapeutics Research and Development Expense (TTM): 10.78M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.78M |
| December 31, 2023 | 15.41M |
| September 30, 2023 | 17.21M |
| June 30, 2023 | 18.59M |
| March 31, 2023 | 23.67M |
| December 31, 2022 | 26.21M |
| September 30, 2022 | 28.17M |
| Date | Value |
|---|---|
| June 30, 2022 | 29.90M |
| March 31, 2022 | 26.92M |
| December 31, 2021 | 23.32M |
| September 30, 2021 | 20.86M |
| June 30, 2021 | 16.81M |
| March 31, 2021 | 12.38M |
| December 31, 2020 | 9.342M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
9.342M
Minimum
Dec 2020
29.90M
Maximum
Jun 2022
19.97M
Average
19.72M
Median
Research and Development Expense (TTM) Benchmarks
| Alpine Immune Sciences Inc (DELISTED) | 83.78M |
| Candel Therapeutics Inc | 23.14M |
| Cyclacel Pharmaceuticals Inc | 16.28M |
| Lipocine Inc | -- |
| GlycoMimetics Inc | 20.68M |